Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company’s lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP).

More:
Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Leave a Reply